In this study, the ER and PR positivity rates of male breast cancer could be over 90%, respectively; the HER2 positivity rate was 10.38%, the incidence of low-expression was 67.93%, and the incidence of ultra-low expression was 12.26%. Here, ERBB2 is linked to breast carcinoma.